ImmuCell Corporation (NASDAQ:ICCC) Short Interest Update

ImmuCell Corporation (NASDAQ:ICCC) saw a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 27,331 shares, an increase of 71.6% from the February 26th total of 15,924 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average daily trading volume, of 13,770 shares, the days-to-cover ratio is presently 2.0 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of ImmuCell from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 24th. One investment analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold”.

Hedge Funds Weigh In On ImmuCell

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its position in shares of ImmuCell by 4.2% in the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after purchasing an additional 2,907 shares during the period. Steadtrust LLC boosted its holdings in shares of ImmuCell by 79.1% during the 4th quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company’s stock worth $349,000 after buying an additional 25,070 shares during the period. Finally, Mesirow Financial Investment Management Inc. boosted its holdings in shares of ImmuCell by 199.6% during the 4th quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock worth $224,000 after buying an additional 24,303 shares during the period. 13.47% of the stock is owned by institutional investors.

ImmuCell Stock Performance

NASDAQ ICCC traded down $0.01 during trading on Friday, reaching $6.52. 9,481 shares of the company’s stock were exchanged, compared to its average volume of 17,627. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.21 and a quick ratio of 1.76. The business has a 50 day moving average price of $6.40 and a 200-day moving average price of $6.11. The stock has a market capitalization of $59.01 million, a P/E ratio of -59.27 and a beta of 0.27. ImmuCell has a fifty-two week low of $4.52 and a fifty-two week high of $7.60.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.